v3.22.4
REVENUE (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Summary of Activity in Accrued Rebates and Chargebacks, Returns, Wholesaler Service Fees and Prompt Pay Discounts The following table provides a summary of activity with respect to the Company’s sales related allowances and accruals related to EXPAREL for the years ended December 31, 2022, 2021 and 2020, as well as ZILRETTA for the years ended December 31, 2022 and 2021 (in thousands):
Returns AllowancesPrompt Payment DiscountsService
Fees		Volume Rebates and ChargebacksGovernment RebatesTotal
Balance at December 31, 2019$540 $962 $1,486 $1,816 $— $4,804 
  Provision794 8,541 6,437 12,345 — 28,117 
  Payments/Adjustments(311)(8,496)(6,755)(12,561)— (28,123)
Balance at December 31, 20201,023 1,007 1,168 1,600 — 4,798 
   Provision3,095 10,388 10,112 17,101 1,139 41,835 
   Payments/Adjustments(757)(10,217)(7,644)(15,207)(378)(34,203)
Balance at December 31, 20213,361 1,178 3,636 3,494 761 12,430 
   Provision1,390 11,145 16,866 48,890 1,641 79,932 
   Payments/Adjustments(3,060)(11,136)(17,309)(46,932)(1,616)(80,053)
Balance at December 31, 2022$1,691 $1,187 $3,193 $5,452 $786 $12,309 
Disaggregation of Revenue The following table represents disaggregated net product sales in the periods presented as follows (in thousands):
Year Ended December 31,
202220212020
Net product sales:
EXPAREL$536,899 $506,515 $413,338 
ZILRETTA105,517 12,683 — 
iovera°15,258 16,162 8,817 
Bupivacaine liposome injectable suspension6,476 3,606 4,459 
Total net product sales$664,150 $538,966 $426,614